Page last updated: 2024-12-06
nsc 338720
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
penclomedine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 60203 |
| CHEMBL ID | 273124 |
| SCHEMBL ID | 188460 |
| MeSH ID | M0162840 |
Synonyms (23)
| Synonym |
|---|
| NCI60_002989 |
| NCIMECH_000533 |
| pyridine,5-dichloro-2,4-dimethoxy-6-(trichloromethyl)- |
| nsc-338720 |
| 108030-77-9 |
| NSC338720 , |
| penclomedine |
| pyridine, 3,5-dichloro-2,4-dimethoxy-6-(trichloromethyl)- |
| nsc 338720 |
| 3,5-dichloro-2,4-dimethoxy-6-(trichloromethyl)pyridine |
| CHEMBL273124 |
| ccris 9406 |
| unii-66q80il7cw |
| 66q80il7cw , |
| CCG-35550 |
| SCHEMBL188460 |
| 3,5-dichloro-2,4-dimethyloxy-6-trichloromethyl-pyridine |
| penclomedine [who-dd] |
| 3,5-dichloro-2,4-dimethoxy-6-(trichloromethyl)pyridine # |
| nsc 338720; pen |
| DTXSID50148365 |
| DB12987 |
| Q27264013 |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " Pharmacokinetic assessment was performed during the first cycle of treatment." | ( Phase I clinical and pharmacokinetic trial of penclomedine using a novel, two-stage trial design for patients with advanced malignancy. Alberti, D; Arzoomanian, RZ; Berlin, J; Feierabend, C; Simon, K; Stewart, JA; Storer, B; Tutsch, KD; Wilding, G, 1998) | 0.3 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " The bioavailability of penclomedine ranged from 28% to 98% (median 73%)." | ( Bioavailability of penclomedine and systemic exposure to 4-O-demethylpenclomedine in patients receiving oral and intravenous penclomedine. Bowling, KM; Collins, J; Donehower, RC; Hartman, NR; O'Reilly, S; Rowinsky, EK; Strong, JM, 2001) | 0.31 |
| " Formulations with particle size 160 nm had the highest relative bioavailability (set at F=1), whereas administration in particle size 720 nm had slightly lower bioavailability (F=0." | ( Intestinal absorption of penclomedine from lipid vehicles in the conscious rat: contribution of emulsification versus digestibility. Campanero, MA; de Smidt, PC; Trocóniz, IF, 2004) | 0.32 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| "On a 1-hour dosing schedule, ataxia, vertigo, nystagmus, and a motor aphasia were the principal toxicities of penclomedine." | ( Phase I and pharmacologic study of penclomedine, a novel alkylating agent, in patients with solid tumors. Bowling, K; Chen, TL; Donehower, RC; Grochow, LB; Hartman, NR; O'Reilly, S; Rowinsky, EK; Struck, RF, 1997) | 0.3 |
| " on a dailyx5-day dosing schedule." | ( The alkylating agent penclomedine induces degeneration of purkinje cells in the rat cerebellum. Molliver, ME; O'Hearn, E; O'Reilly, S; Rowinsky, EK; Struck, RF, 2003) | 0.32 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (3)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID121289 | Tumor growth delay in comparison vehicle-treated control, difference in the median time poststaging for tumors of the treated (T) group to double twice in mass compared to the median of the control (C) group ce | 2002 | Journal of medicinal chemistry, Feb-28, Volume: 45, Issue:5 | Synthesis and antitumor activity of several new analogues of penclomedine and its metabolites. |
| AID124605 | Number of tumor-free survivors in a group of five mice | 2002 | Journal of medicinal chemistry, Feb-28, Volume: 45, Issue:5 | Synthesis and antitumor activity of several new analogues of penclomedine and its metabolites. |
| AID117482 | In vivo optimal (ip) dosage (<LD10) against subcutaneously implanted human mammary tumor xenograft MX-1 on a five-successive day schedule in Athymic NCr-nu/nu mice | 2002 | Journal of medicinal chemistry, Feb-28, Volume: 45, Issue:5 | Synthesis and antitumor activity of several new analogues of penclomedine and its metabolites. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (24)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (4.17) | 18.7374 |
| 1990's | 13 (54.17) | 18.2507 |
| 2000's | 10 (41.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 5 (19.23%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 21 (80.77%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||